CompaniesInnate Immunotherapeutics

Innate Immunotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

2

As Collaborator

1

Total Enrollment

174

By Phase

PHASE1/PHASE2: 2PHASE2: 1

By Status

COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Today
NCT01191996
NCT02228213
NCT03399903
Hover over trial bars to see details

Recent Trials

NCT03399903Collaborator
Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection
PHASE1/PHASE2Completed
47 participants
Started: May 1, 2017 · Completed: Mar 22, 2019
NCT02228213Lead Sponsor
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
PHASE2Completed
93 participants
Started: Oct 31, 2014 · Completed: Jun 30, 2017
NCT01191996Lead Sponsor
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
PHASE1/PHASE2Completed
34 participants
Started: Aug 31, 2010 · Completed: Nov 30, 2012